The Zhitong Finance App learned that Poseida Therapeutics (PSTX.US), a leading company in the field of clinical-stage allogeneic cell therapy and gene drugs, announced that it will be acquired by Roche Holdings for a total equity value of about 1.5 billion US dollars. The acquisition includes $9.00 in cash per share, with additional non-tradable contingent value rights (CVR). Shareholders can expect to receive an additional cash payment of up to $4.00 per share after reaching certain milestones. The entire transaction is expected to be successfully completed in the first quarter of 2025. Poseida will continue to advance the development of its non-viral CAR-T therapies and genetic drugs as part of Roche Pharmaceuticals division.

The Zhitong Finance App learned that Poseida Therapeutics (PSTX.US), a leading company in the field of clinical-stage allogeneic cell therapy and gene drugs, announced that it will be acquired by Roche Holdings for a total equity value of about 1.5 billion US dollars. The acquisition includes $9.00 in cash per share, with additional non-tradable contingent value rights (CVR). Shareholders can expect to receive an additional cash payment of up to $4.00 per share after reaching certain milestones. The entire transaction is expected to be successfully completed in the first quarter of 2025. Poseida will continue to advance the development of its non-viral CAR-T therapies and genetic drugs as part of Roche Pharmaceuticals division.